These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16981834)

  • 1. Novel targets in prostate cancer.
    Berthold DR; Moore MJ
    Expert Opin Ther Targets; 2006 Oct; 10(5):777-80. PubMed ID: 16981834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for prostate cancer.
    Asatiani E; Gelmann EP
    Expert Opin Ther Targets; 2005 Apr; 9(2):283-98. PubMed ID: 15934916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Horizon scanning for novel therapeutics for the treatment of prostate cancer.
    Bianchini D; Zivi A; Sandhu S; de Bono JS
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1487-502. PubMed ID: 20868208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell mates: paracrine and stromal targets for prostate cancer therapy.
    Sluka P; Davis ID
    Nat Rev Urol; 2013 Aug; 10(8):441-51. PubMed ID: 23857181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.
    Levy O; Brennen WN; Han E; Rosen DM; Musabeyezu J; Safaee H; Ranganath S; Ngai J; Heinelt M; Milton Y; Wang H; Bhagchandani SH; Joshi N; Bhowmick N; Denmeade SR; Isaacs JT; Karp JM
    Biomaterials; 2016 Jun; 91():140-150. PubMed ID: 27019026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review.
    Bhosale RR; Gangadharappa HV; Hani U; Ali M Osmani R; Vaghela R; Kulkarni PK; Koganti VS
    Curr Drug Targets; 2017; 18(11):1233-1249. PubMed ID: 27296312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options in hormone-refractory prostate cancer: current and future approaches.
    Harris KA; Reese DM
    Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agents targeting prostate cancer bone metastasis.
    Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle therapeutics for prostate cancer treatment.
    Sanna V; Sechi M
    Nanomedicine; 2012 Sep; 8 Suppl 1():S31-6. PubMed ID: 22640911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting prostate cancer stem cells.
    Crea F; Mathews LA; Farrar WL; Hurt EM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1105-13. PubMed ID: 19925394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the relaxin hormonal pathway in prostate cancer.
    Neschadim A; Summerlee AJ; Silvertown JD
    Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1 is a promising therapeutic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Curr Cancer Drug Targets; 2007 May; 7(3):259-71. PubMed ID: 17504123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy for advanced prostate cancer: Looking through new lenses.
    Vogiatzi P; Cassone M; Claudio L; Claudio PP
    Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
    Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel targets in pancreatic cancer: focus on future paths to therapy.
    Cohen SJ; Burtness BA
    Expert Opin Ther Targets; 2006 Oct; 10(5):771-5. PubMed ID: 16981833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New molecular targets in advanced prostate cancer.
    Dawson NA
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug design strategies for the treatment of prostate cancer.
    Lauer RC; Friend SC; Rietz C; Pasqualini R; Arap W
    Expert Opin Drug Discov; 2015 Jan; 10(1):81-90. PubMed ID: 25366417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current prospects and challenges of nanomedicine delivery in prostate cancer therapy.
    Gupta S; Gupta PK; Dharanivasan G; Verma RS
    Nanomedicine (Lond); 2017 Dec; 12(23):2675-2692. PubMed ID: 29098929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.